Medications are often used off label when they are found to have properties or effects that could potentially benefit a disease state or condition they were not originally intended for. Up to one-third of all prescriptions for common medications in the United States are used off label.1 Glucagon-like peptide 1 (GLP-1) receptor agonists are a class of medications that were first approved in 2005 for type 2 diabetes (T2D).2,3 However, since their original entry into the market, GLP-1 receptor agonists have gained FDA approval and have established significant roles in therapy for cardiovascular disease, obesity, and kidney disease. Interestingly, emerging data suggest that this class of medications may have roles in other—somewhat unrelated—conditions.
